Tumor-platelet interaction in solid tumors

International Journal of Cancer

Volumn 130, Issue 12, 2012, Pages 2747-2760

  Buergy, Daniel ^a   Wenz, Frederik ^a   Groden, Christoph ^a   Brockmann, Marc A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

angiogenesis; cancer; metastasis; platelets; thrombocytosis

Indexed keywords

ACETYLSALICYLIC ACID; BEVACIZUMAB; ERYTHROPOIETIN; FIBRINOGEN RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 3; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; ONCOSTATIN M; STEM CELL FACTOR; THROMBOPOIETIN; VASCULOTROPIN;

CANCER INVASION; CIRCULATING TUMOR CELL; CYTOKINE RELEASE; GLIOBLASTOMA; GLIOMA; HEMATOPOIETIC STEM CELL; HUMAN; MELANOMA; METASTASIS; NATURAL KILLER CELL; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOLID TUMOR; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS; THROMBOCYTOSIS; TUMOR BLEEDING; TUMOR GROWTH; TUMOR VASCULARIZATION;

BLOOD PLATELETS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PLATELET COUNT; SURVIVAL; THROMBOCYTOSIS;

EID: 84859911681     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27441     Document Type: Review

References (171)

1. Riess L,. Zur pathologischen Anatomie des Blutes. Arch Anat Physiol Wissensch Med 1872; 39: 237-49.
2. Billroth T,. Lectures on Surgical Pathology and Therapeutics: A Handbook for Students and Practitionersed. London: The New Sydenham Society, 1878.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
4. Ruffie P, Feld R, Minkin S, Cormier Y, Boutan-Laroze A, Ginsberg R, Ayoub J, Shepherd FA, Evans WK, Figueredo A, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 1989; 7: 1157-68. (Pubitemid 19196542)
5. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ,. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113: 723-31. (Pubitemid 28130949)
6. Pedersen LM, Milman N,. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J 1996; 9: 1826-30. (Pubitemid 26294751)
7. Cox G, Walker RA, Andi A, Steward WP, O'Byrne KJ,. Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer. Lung Cancer 2000; 29: 169-77.
8. Brown KM, Domin C, Aranha GV, Yong S, Shoup M,. Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. Am J Surg 2005; 189: 278-82. (Pubitemid 40431945)
9. Dominguez I, Crippa S, Thayer SP, Hung YP, Ferrone CR, Warshaw AL, Fernandez-Del Castillo C,. Preoperative platelet count and survival prognosis in resected pancreatic ductal adenocarcinoma. World J Surg 2008; 32: 1051-6.
10. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Satomi T,. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 2002; 9: 287-91. (Pubitemid 34298634)
11. Shimada H, Oohira G, Okazumi S, Matsubara H, Nabeya Y, Hayashi H, Takeda A, Gunji Y, Ochiai T,. Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg 2004; 198: 737-41. (Pubitemid 38542902)
12. Nouso K, Ito Y, Kuwaki K, Kobayashi Y, Nakamura S, Ohashi Y, Yamamoto K,. Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis. Br J Cancer 2008; 98: 1161-5. (Pubitemid 351481668)
13. Sengelov L, Kamby C, Schou G, von der Maase H,. Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract. Cancer 1994; 74: 123-33. (Pubitemid 24187620)
14. Symbas NP, Townsend MF, El-Galley R, Keane TE, Graham SD, Petros JA,. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 2000; 86: 203-7. (Pubitemid 30621216)
15. O'Keefe SC, Marshall FF, Issa MM, Harmon MP, Petros JA,. Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy. J Urol 2002; 168: 1378-80. (Pubitemid 35034126)
16. Hernandez E, Lavine M, Dunton CJ, Gracely E, Parker J,. Poor prognosis associated with thrombocytosis in patients with cervical cancer. Cancer 1992; 69: 2975-7.
17. Rodriguez GC, Clarke-Pearson DL, Soper JT, Berchuck A, Synan I, Dodge RK,. The negative prognostic implications of thrombocytosis in women with stage IB cervical cancer. Obstet Gynecol 1994; 83: 445-8. (Pubitemid 24067817)
18. Lopes A, Daras V, Cross PA, Robertson G, Beynon G, Monaghan JM,. Thrombocytosis as a prognostic factor in women with cervical cancer. Cancer 1994; 74: 90-2. (Pubitemid 24187615)
19. Hernandez E, Heller PB, Whitney C, Diana K, Delgado G,. Thrombocytosis in surgically treated stage IB squamous cell cervical carcinoma (A Gynecologic Oncology Group study). Gynecol Oncol 1994; 55: 328-32.
20. Hernandez E, Donohue KA, Anderson LL, Heller PB, Stehman FB,. The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2000; 78: 137-42. (Pubitemid 30650343)
21. Gucer F, Moser F, Tamussino K, Reich O, Haas J, Arikan G, Petru E, Winter R,. Thrombocytosis as a prognostic factor in endometrial carcinoma. Gynecol Oncol 1998; 70: 210-4. (Pubitemid 28430931)
22. Gerestein CG, Eijkemans MJ, de Jong D, van der Burg ME, Dykgraaf RH, Kooi GS, Baalbergen A, Burger CW, Ansink AC,. The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma. BJOG 2009; 116: 372-80.
23. Taucher S, Salat A, Gnant M, Kwasny W, Mlineritsch B, Menzel RC, Schmid M, Smola MG, Stierer M, Tausch C, Galid A, Steger G, et al. Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost 2003; 89: 1098-106. (Pubitemid 36798163)
24. Lavie O, Comerci G, Daras V, Bolger BS, Lopes A, Monaghan JM,. Thrombocytosis in women with vulvar carcinoma. Gynecol Oncol 1999; 72: 82-6. (Pubitemid 29045452)
25. Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, Houghton AN,. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 1993; 72: 3091-8. (Pubitemid 23335058)
26. Chen MH, Chang PM, Chen PM, Tzeng CH, Chu PY, Chang SY, Yang MH,. Prognostic significance of a pretreatment hematologic profile in patients with head and neck cancer. J Cancer Res Clin Oncol 2009; 135: 1783-90.
27. Brockmann MA, Giese A, Mueller K, Kaba FJ, Lohr F, Weiss C, Gottschalk S, Nolte I, Leppert J, Tuettenberg J, Groden C,. Preoperative thrombocytosis predicts poor survival in patients with glioblastoma. Neuro Oncol 2007; 9: 335-42. (Pubitemid 47169666)
28. Ruka W, Rutkowski P, Kaminska J, Rysinska A, Steffen J,. Alterations of routine blood tests in adult patients with soft tissue sarcomas: relationships to cytokine serum levels and prognostic significance. Ann Oncol 2001; 12: 1423-32. (Pubitemid 33100249)
29. Suzuki K, Aiura K, Kitagou M, Hoshimoto S, Takahashi S, Ueda M, Kitajima M,. Platelets counts closely correlate with the disease-free survival interval of pancreatic cancer patients. Hepatogastroenterology 2004; 51: 847-53. (Pubitemid 38590980)
30. Schwarz RE, Keny H,. Preoperative platelet count predicts survival after resection of periampullary adenocarcinoma. Hepatogastroenterology 2001; 48: 1493-8. (Pubitemid 33010454)
31. Schofield R,. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 1978; 4: 7-25. (Pubitemid 8376317)
32. Avecilla ST, Hattori K, Heissig B, Tejada R, Liao F, Shido K, Jin DK, Dias S, Zhang F, Hartman TE, Hackett NR, Crystal RG, et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med 2004; 10: 64-71. (Pubitemid 38524700)
33. Arai F, Hirao A, Suda T,. Regulation of hematopoiesis and its interaction with stem cell niches. Int J Hematol 2005; 82: 371-6. (Pubitemid 46638683)
34. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Bringhurst FR, Milner LA, Kronenberg HM, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425: 841-6. (Pubitemid 37351468)
35. Kiel MJ, Yilmaz OH, Iwashita T, Terhorst C, Morrison SJ,. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005; 121: 1109-21. (Pubitemid 40884400)
36. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, Ross J, Haug J, Johnson T, Feng JQ, Harris S, Wiedemann LM, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003; 425: 836-41. (Pubitemid 37351467)
37. Hooper AT, Butler J, Petit I, Rafii S,. Does N-cadherin regulate interaction of hematopoietic stem cells with their niches? Cell Stem Cell 2007; 1: 127-9. (Pubitemid 47215596)
38. Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR, Crystal RG, Besmer P, Lyden D, Moore MA, Werb Z, Rafii S,. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002; 109: 625-37. (Pubitemid 34628725)
39. Hattori K, Heissig B, Tashiro K, Honjo T, Tateno M, Shieh JH, Hackett NR, Quitoriano MS, Crystal RG, Rafii S, Moore MA,. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 2001; 97: 3354-60.
40. Hattori K, Dias S, Heissig B, Hackett NR, Lyden D, Tateno M, Hicklin DJ, Zhu Z, Witte L, Crystal RG, Moore MA, Rafii S,. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 2001; 193: 1005-14. (Pubitemid 32436194)
41. Heissig B, Werb Z, Rafii S, Hattori K,. Role of c-kit/Kit ligand signaling in regulating vasculogenesis. Thromb Haemost 2003; 90: 570-6. (Pubitemid 37287623)
42. Zaman K, Driscoll R, Hahn D, Werffeli P, Goodman SL, Bauer J, Leyvraz S, Lejeune F, Stupp R, Ruegg C,. Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy. Int J Cancer 2006; 118: 755-64. (Pubitemid 43076028)
43. de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, Darbonne WC, Henzel WJ, Wong SC, Kuang WJ, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994; 369: 533-8.
44. Lok S, Kaushansky K, Holly RD, Kuijper JL, Lofton-Day CE, Oort PJ, Grant FJ, Heipel MD, Burkhead SK, Kramer JM, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369: 565-8. (Pubitemid 24192525)
45. Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, Forstrom JW, Buddle MM, Oort PJ, Hagen FS, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994; 369: 568-71. (Pubitemid 24192526)
46. Nickerson HJ, Silberman TL, McDonald TP,. Hepatoblastoma, thrombocytosis, and increased thrombopoietin. Cancer 1980; 45: 315-7. (Pubitemid 10212197)
47. Yamaguchi H, Ishii E, Hayashida Y, Hirata Y, Sakai R, Miyazaki S,. Mechanism of thrombocytosis in hepatoblastoma: a case report. Pediatr Hematol Oncol 1996; 13: 539-44. (Pubitemid 26396897)
48. Shimada Y, Kato T, Ogami K, Horie K, Kokubo A, Kudo Y, Maeda E, Sohma Y, Akahori H, Kawamura K, et al. Production of thrombopoietin (TPO) by rat hepatocytes and hepatoma cell lines. Exp Hematol 1995; 23: 1388-96. (Pubitemid 26046526)
49. Furuhashi M, Miyabe Y, Oda H,. A case of thrombopoietin-producing ovarian carcinoma confirmed by immunohistochemistry. Gynecol Oncol 1999; 74: 278-81. (Pubitemid 29377226)
50. Ciurea SO, Hoffman R,. Cytokines for the treatment of thrombocytopenia. Semin Hematol 2007; 44: 166-82. (Pubitemid 47031227)
51. De Vita F, Romano C, Orditura M, Galizia G, Martinelli E, Lieto E, Catalano G,. Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J Interferon Cytokine Res 2001; 21: 45-52. (Pubitemid 32106090)
52. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992; 52: 3317-22.
53. Paule B, Belot J, Rudant C, Coulombel C, Abbou CC,. The importance of IL-6 protein expression in primary human renal cell carcinoma: an immunohistochemical study. J Clin Pathol 2000; 53: 388-90. (Pubitemid 30256908)
54. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M,. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000; 6: 2702-6. (Pubitemid 30482107)
55. Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA,. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 1994; 73: 1882-8. (Pubitemid 24101966)
56. Takeuchi E, Ito M, Mori M, Yamaguchi T, Nakagawa M, Yokota S, Nishikawa H, Sakuma-Mochizuki J, Hayashi S, Ogura T,. Lung cancer producing interleukin-6. Intern Med 1996; 35: 212-4. (Pubitemid 126462528)
57. Corbeil J, Evans LA, Vasak E, Cooper DA, Penny R,. Culture and properties of cells derived from Kaposi sarcoma. J Immunol 1991; 146: 2972-6.
58. Choi C, Gillespie GY, Van Wagoner NJ, Benveniste EN,. Fas engagement increases expression of interleukin-6 in human glioma cells. J Neurooncol 2002; 56: 13-9. (Pubitemid 34256613)
59. Eustace D, Han X, Gooding R, Rowbottom A, Riches P, Heyderman E,. Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol Oncol 1993; 50: 15-9. (Pubitemid 23235504)
60. Chen Q, Solar G, Eaton DL, de Sauvage FJ,. IL-3 does not contribute to platelet production in c-Mpl-deficient mice. Stem Cells 1998; 16 (Suppl 2): 31-6.
61. Gainsford T, Nandurkar H, Metcalf D, Robb L, Begley CG, Alexander WS,. The residual megakaryocyte and platelet production in c-mpl-deficient mice is not dependent on the actions of interleukin-6, interleukin-11, or leukemia inhibitory factor. Blood 2000; 95: 528-34. (Pubitemid 30041665)
62. Gainsford T, Roberts AW, Kimura S, Metcalf D, Dranoff G, Mulligan RC, Begley CG, Robb L, Alexander WS,. Cytokine production and function in c-mpl-deficient mice: no physiologic role for interleukin-3 in residual megakaryocyte and platelet production. Blood 1998; 91: 2745-52. (Pubitemid 28227524)
63. Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, Theurl I, Widder W, Molnar C, Ludwiczek O, Atkins MB, Mier JW, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 2001; 98: 2720-5.
64. Kishimoto T, Akira S, Narazaki M, Taga T,. Interleukin-6 family of cytokines and gp130. Blood 1995; 86: 1243-54.
65. Chen Y, Deng J, Fujimoto J, Kadara H, Men T, Lotan D, Lotan R,. Gprc5a deletion enhances the transformed phenotype in normal and malignant lung epithelial cells by eliciting persistent Stat3 signaling induced by autocrine leukemia inhibitory factor. Cancer Res 2010; 70: 8917-26.
66. Penuelas S, Anido J, Prieto-Sanchez RM, Folch G, Barba I, Cuartas I, Garcia-Dorado D, Poca MA, Sahuquillo J, Baselga J, Seoane J,. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 2009; 15: 315-27.
67. Baxter EW, Milner J,. p53 Regulates LIF expression in human medulloblastoma cells. J Neurooncol 2010; 97: 373-82.
68. Arthan D, Hong SK, Park JI,. Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells. Cancer Lett 2010; 297: 31-41.
69. Girard BM, Cheppudira BP, Malley SE, Schutz KC, May V, Vizzard MA,. Increased expression of interleukin-6 family members and receptors in urinary bladder with cyclophosphamide-induced bladder inflammation in female rats. Front Neurosci 2011; 5: 20.
70. Chen LL, Ye F, Lu WG, Yu Y, Chen HZ, Xie X,. Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma. J Obstet Gynaecol Res 2009; 35: 212-8.
71. Gouin F, Heymann D, Raher S, De Groote D, Passuti N, Daculsi G, Godard A,. Increased levels of leukaemia inhibitory factor (LIF) in urine and tissue culture supernatant from human primary bone tumours. Cytokine 1998; 10: 110-4. (Pubitemid 28077709)
72. Zarling JM, Shoyab M, Marquardt H, Hanson MB, Lioubin MN, Todaro GJ,. Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. Proc Natl Acad Sci USA 1986; 83: 9739-43. (Pubitemid 17223432)
73. Douglas AM, Grant SL, Goss GA, Clouston DR, Sutherland RL, Begley CG,. Oncostatin M induces the differentiation of breast cancer cells. Int J Cancer 1998; 75: 64-73. (Pubitemid 28113979)
74. Grant SL, Begley CG,. The oncostatin M signalling pathway: reversing the neoplastic phenotype? Mol Med Today 1999; 5: 406-12. (Pubitemid 29399990)
75. Rygaard K, Nakamura T, Spang-Thomsen M,. Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br J Cancer 1993; 67: 37-46. (Pubitemid 23034921)
76. Inoue M, Kyo S, Fujita M, Enomoto T, Kondoh G,. Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res 1994; 54: 3049-53. (Pubitemid 24187794)
77. Toyota M, Hinoda Y, Takaoka A, Makiguchi Y, Takahashi T, Itoh F, Imai K, Yachi A,. Expression of c-kit and kit ligand in human colon carcinoma cells. Tumour Biol 1993; 14: 295-302. (Pubitemid 23357718)
78. Hassan S, Kinoshita Y, Kawanami C, Kishi K, Matsushima Y, Ohashi A, Funasaka Y, Okada A, Maekawa T, He-Yao W, Chiba T,. Expression of protooncogene c-kit and its ligand stem cell factor (SCF) in gastric carcinoma cell lines. Dig Dis Sci 1998; 43: 8-14. (Pubitemid 28081634)
79. Mroczko B, Szmitkowski M,. Hematopoietic cytokines as tumor markers. Clin Chem Lab Med 2004; 42: 1347-54. (Pubitemid 40057821)
80. Mroczko B, Szmitkowski M, Okulczyk B,. Hematopoietic growth factors in colorectal cancer patients. Clin Chem Lab Med 2003; 41: 646-51. (Pubitemid 36722819)
81. Mroczko B, Szmitkowski M, Niklinski J,. Stem cell factor and granulocyte-macrophage-colony stimulating factor as candidates for tumour markers for non-small-cell lung cancer. Clin Chem Lab Med 1999; 37: 959-62. (Pubitemid 30011573)
82. Dentelli P, Rosso A, Calvi C, Ghiringhello B, Garbarino G, Camussi G, Pegoraro L, Brizzi MF,. IL-3 affects endothelial cell-mediated smooth muscle cell recruitment by increasing TGF beta activity: potential role in tumor vessel stabilization. Oncogene 2004; 23: 1681-92. (Pubitemid 38445160)
83. Dentelli P, Rosso A, Garbarino G, Calvi C, Lombard E, Di Stefano P, Defilippi P, Pegoraro L, Brizzi MF,. The interaction between KDR and interleukin-3 receptor (IL-3R) beta common modulates tumor neovascularization. Oncogene 2005; 24: 6394-405. (Pubitemid 41486473)
84. Deans DA, Wigmore SJ, Gilmour H, Paterson-Brown S, Ross JA, Fearon KC,. Elevated tumour interleukin-1beta is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancer. Br J Cancer 2006; 95: 1568-75. (Pubitemid 44863361)
85. Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A, Schwall R, Schnitt SJ, Guida A, Hastings HM, Andres J, Turkel G, Polverini PJ, et al. Expression of interleukin-1beta in human breast arcinoma. Cancer 1997; 80: 421-34. (Pubitemid 27323412)
86. Yoshida N, Ikemoto S, Narita K, Sugimura K, Wada S, Yasumoto R, Kishimoto T, Nakatani T,. Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma. Br J Cancer 2002; 86: 1396-400. (Pubitemid 34548059)
87. Hong DY, Lee BJ, Lee JC, Choi JS, Wang SG, Ro JH,. Expression of VEGF, HGF, IL-6, IL-8, MMP-9, telomerase in peripheral blood of patients with head and neck squamous cell carcinoma. Clin Exp Otorhinolaryngol 2009; 2: 186-92.
88. Cao D, Hou M, Guan YS, Jiang M, Yang Y, Gou HF,. Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. BMC Cancer 2009; 9: 432.
89. Pau EC, Arias FC, Pelaez EC, Trueba IM, Hernandez IS, Molina GM, Balsalobre RM, Lopez SS, Gomez-Pinillos A, Toledo Lobo MD,. Vascular endothelial growth factor (VEGF) serum levels are associated with survival in early stages of lung cancer patients. Cancer Invest 2010; 120: 393-8.
90. Liang YX, He HC, Han ZD, Bi XC, Dai QS, Ye YK, Qin WJ, Zeng GH, Zhu G, Xu CL, Zhong WD,. CD147 and VEGF expression in advanced renal cell carcinoma and their prognostic value. Cancer Invest 2009; 27: 788-93.
91. Schreuder WO, Ting WC, Smith S, Jacobs A,. Testosterone, erythropoietin and anaemia in patients with disseminated bronchial cancer. Br J Haematol 1984; 57: 521-6. (Pubitemid 14082102)
92. Tas F, Oguz H, Argon A, Duranyildiz D, Camlica H, Yasasever V, Topuz E,. The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma. Med Oncol 2005; 22: 241-6. (Pubitemid 41176320)
93. Gross AJ, Wolff M, Fandrey J, Miersch WD, Dieckmann KP, Jelkmann W,. Prevalence of paraneoplastic erythropoietin production by renal cell carcinomas. Clin Investig 1994; 72: 337-40. (Pubitemid 24171917)
94. Kew MC, Fisher JW,. Serum erythropoietin concentrations in patients with hepatocellular carcinoma. Cancer 1986; 58: 2485-8. (Pubitemid 17191612)
95. Roos E,. Cellular adhesion, invasion and metastasis. Biochim Biophys Acta 1984; 738: 263-84. (Pubitemid 15151934)
96. Liotta LA,. Cancer cell invasion and metastasis. Sci Am 1992; 266: 54-9, 62-3.
97. Gay LJ, Felding-Habermann B,. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011; 11: 123-34.
98. Tzanakakis GN, Agarwal KC, Vezeridis MP,. Prevention of human pancreatic cancer cell-induced hepatic metastasis in nude mice by dipyridamole and its analog RA-233. Cancer 1993; 71: 2466-71. (Pubitemid 23100478)
99. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirouskova M, Degen JL,. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005; 105: 178-85. (Pubitemid 40053080)
100. Stoelcker B, Hafner M, Orosz P, Nieswandt B, Mannel DN,. Role of adhesion molecules and platelets in TNF-induced adhesion of tumor cells to endothelial cells: implications for experimental metastasis. J Inflamm 1995; 46: 155-67.
101. Mahalingam M, Ugen KE, Kao KJ, Klein PA,. Functional role of platelets in experimental metastasis studied with cloned murine fibrosarcoma cell variants. Cancer Res 1988; 48: 1460-4. (Pubitemid 18091189)
102. Nieswandt B, Hafner M, Echtenacher B, Mannel DN,. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999; 59: 1295-300. (Pubitemid 29136261)
103. Karpatkin S, Pearlstein E, Ambrogio C, Coller BS,. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest 1988; 81: 1012-9.
104. Talmadge JE, Meyers KM, Prieur DJ, Starkey JR,. Role of NK cells in tumour growth and metastasis in beige mice. Nature 1980; 284: 622-4. (Pubitemid 10070870)
105. Hanna N,. The role of natural killer cells in the control of tumor growth and metastasis. Biochim Biophys Acta 1985; 780: 213-26.
106. Wiltrout RH, Herberman RB, Zhang SR, Chirigos MA, Ortaldo JR, Green KM, Jr., Talmadge JE,. Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver. J Immunol 1985; 134: 4267-75. (Pubitemid 15029660)
107. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A,. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 2001; 98: 3352-7. (Pubitemid 32220849)
108. Betz SA, Foucar K, Head DR, Chen IM, Willman CL,. False-positive flow cytometric platelet glycoprotein IIb/IIIa expression in myeloid leukemias secondary to platelet adherence to blasts. Blood 1992; 79: 2399-403.
109. Placke T, Kopp HG, Salih HR,. Modulation of natural killer cell anti-tumor reactivity by platelets. J Innate Immun 2011; 3: 374-82.
110. Erpenbeck L, Schon MP,. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood 2010; 115: 3427-36.
111. Jurasz P, Alonso-Escolano D, Radomski MW,. Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol 2004; 143: 819-26. (Pubitemid 39664840)
112. Gersuk GM, Westermark B, Mohabeer AJ, Challita PM, Pattamakom S, Pattengale PK,. Inhibition of human natural killer cell activity by platelet-derived growth factor (PDGF). III. Membrane binding studies and differential biological effect of recombinant PDGF isoforms. Scand J Immunol 1991; 33: 521-32.
113. Kopp HG, Placke T, Salih HR,. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res 2009; 69: 7775-83.
114. Li N,. Platelet-lymphocyte cross-talk. J Leukoc Biol 2008; 83: 1069-78. (Pubitemid 351960338)
115. Placke T, Kopp HG, Salih HR,. Glucocorticoid-induced TNFR-related (GITR) protein and its ligand in antitumor immunity: functional role and therapeutic modulation. Clin Dev Immunol 2010; 2010: 239083.
116. Tzanakakis GN, Agarwal KC, Veronikis DK, Vezeridis MP,. Effects of antiplatelet agents alone or in combinations on platelet aggregation and on liver metastases from a human pancreatic adenocarcinoma in the nude mouse. J Surg Oncol 1991; 48: 45-50.
117. Honn KV, Cicone B, Skoff A,. Prostacyclin: a potent antimetastatic agent. Science 1981; 212: 1270-2. (Pubitemid 11087831)
118. Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, Coughlin SR,. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 2004; 104: 397-401. (Pubitemid 38900020)
119. Bakewell SJ, Nestor P, Prasad S, Tomasson MH, Dowland N, Mehrotra M, Scarborough R, Kanter J, Abe K, Phillips D, Weilbaecher KN,. Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci USA 2003; 100: 14205-10. (Pubitemid 37499215)
120. Amirkhosravi A, Mousa SA, Amaya M, Blaydes S, Desai H, Meyer T, Francis JL,. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb Haemost 2003; 90: 549-54. (Pubitemid 37138780)
121. Kamat SG, Turner NA, Konstantopoulos K, Hellums JD, McIntire LV, Kleiman NS, Moake JL,. Effects of Integrelin on platelet function in flow models of arterial thrombosis. J Cardiovasc Pharmacol 1997; 29: 156-63. (Pubitemid 27097716)
122. Dardik R, Kaufmann Y, Savion N, Rosenberg N, Shenkman B, Varon D,. Platelets mediate tumor cell adhesion to the subendothelium under flow conditions: involvement of platelet GPIIb-IIIa and tumor cell alpha(v) integrins. Int J Cancer 1997; 70: 201-7. (Pubitemid 27107418)
123. Burdick MM, Konstantopoulos K,. Platelet-induced enhancement of LS174T colon carcinoma and THP-1 monocytoid cell adhesion to vascular endothelium under flow. Am J Physiol Cell Physiol 2004; 287: C539-47. (Pubitemid 38955245)
124. Felding-Habermann B, Habermann R, Saldivar E, Ruggeri ZM,. Role of beta3 integrins in melanoma cell adhesion to activated platelets under flow. J Biol Chem 1996; 271: 5892-900.
125. Malik AB,. Pulmonary microembolism. Physiol Rev 1983; 63: 1114-207. (Pubitemid 13048721)
126. Poggi A, Stella M, Donati MB,. The importance of blood cell-vessel wall interactions in tumour metastasis. Baillieres Clin Haematol 1993; 6: 731-52. (Pubitemid 23306588)
127. Nash GF, Turner LF, Scully MF, Kakkar AK,. Platelets and cancer. Lancet Oncol 2002; 3: 425-30. (Pubitemid 36958273)
128. Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond JP, Cahill DJ, Emili A, Fitzgerald DJ, Maguire PB,. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004; 103: 2096-104. (Pubitemid 38326225)
129. Piersma SR, Broxterman HJ, Kapci M, de Haas RR, Hoekman K, Verheul HM, Jimenez CR,. Proteomics of the TRAP-induced platelet releasate. J Proteomics 2009; 72: 91-109.
130. Pinedo HM, Verheul HM, D'Amato RJ, Folkman J,. Involvement of platelets in tumour angiogenesis? Lancet 1998; 352: 1775-7. (Pubitemid 28534972)
131. Fernandez-Patron C, Martinez-Cuesta MA, Salas E, Sawicki G, Wozniak M, Radomski MW, Davidge ST,. Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2. Thromb Haemost 1999; 82: 1730-5.
132. Jurasz P, Chung AW, Radomski A, Radomski MW,. Nonremodeling properties of matrix metalloproteinases: the platelet connection. Circ Res 2002; 90: 1041-3. (Pubitemid 34627901)
133. Mohle R, Green D, Moore MA, Nachman RL, Rafii S,. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997; 94: 663-8. (Pubitemid 27053690)
134. Wartiovaara U, Salven P, Mikkola H, Lassila R, Kaukonen J, Joukov V, Orpana A, Ristimaki A, Heikinheimo M, Joensuu H, Alitalo K, Palotie A,. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost 1998; 80: 171-5. (Pubitemid 28353517)
135. Heldin CH, Westermark B, Wasteson A,. Platelet-derived growth factor. Isolation by a large-scale procedure and analysis of subunit composition. Biochem J 1981; 193: 907-13.
136. Kaplan DR, Chao FC, Stiles CD, Antoniades HN, Scher CD,. Platelet alpha granules contain a growth factor for fibroblasts. Blood 1979; 53: 1043-52. (Pubitemid 10238908)
137. Ben-Ezra J, Sheibani K, Hwang DL, Lev-Ran A,. Megakaryocyte synthesis is the source of epidermal growth factor in human platelets. Am J Pathol 1990; 137: 755-9. (Pubitemid 20337790)
138. Nakamura T, Tomita Y, Hirai R, Yamaoka K, Kaji K, Ichihara A,. Inhibitory effect of transforming growth factor-beta on DNA synthesis of adult rat hepatocytes in primary culture. Biochem Biophys Res Commun 1985; 133: 1042-50. (Pubitemid 16142884)
139. Karey KP, Sirbasku DA,. Human platelet-derived mitogens. II. Subcellular localization of insulinlike growth factor I to the alpha-granule and release in response to thrombin. Blood 1989; 74: 1093-100. (Pubitemid 19210029)
140. Karey KP, Marquardt H, Sirbasku DA,. Human platelet-derived mitogens. I. Identification of insulinlike growth factors I and II by purification and N alpha amino acid sequence analysis. Blood 1989; 74: 1084-92. (Pubitemid 19210028)
141. White RR, Shan S, Rusconi CP, Shetty G, Dewhirst MW, Kontos CD, Sullenger BA,. Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc Natl Acad Sci USA 2003; 100: 5028-33. (Pubitemid 36542652)
142. Hla T,. Physiological and pathological actions of sphingosine 1-phosphate. Semin Cell Dev Biol 2004; 15: 513-20. (Pubitemid 38953947)
143. English D, Welch Z, Kovala AT, Harvey K, Volpert OV, Brindley DN, Garcia JG,. Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis. FASEB J 2000; 14: 2255-65.
144. Galt SW, Lindemann S, Allen L, Medd DJ, Falk JM, McIntyre TM, Prescott SM, Kraiss LW, Zimmerman GA, Weyrich AS,. Outside-in signals delivered by matrix metalloproteinase-1 regulate platelet function. Circ Res 2002; 90: 1093-9. (Pubitemid 34627908)
145. Baenziger NL, Brodie GN, Majerus PW,. Isolation and properties of a thrombin-sensitive protein of human platelets. J Biol Chem 1972; 247: 2723-31.
146. Folkman J, Kalluri R,. Cancer without disease. Nature 2004; 427: 787. (Pubitemid 38297724)
147. Brill A, Dashevsky O, Rivo J, Gozal Y, Varon D,. Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization. Cardiovasc Res 2005; 67: 30-8. (Pubitemid 40798290)
148. Brill A, Elinav H, Varon D,. Differential role of platelet granular mediators in angiogenesis. Cardiovasc Res 2004; 63: 226-35. (Pubitemid 38900837)
149. Kisucka J, Butterfield CE, Duda DG, Eichenberger SC, Saffaripour S, Ware J, Ruggeri ZM, Jain RK, Folkman J, Wagner DD,. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci USA 2006; 103: 855-60. (Pubitemid 43212187)
150. Rhee JS, Black M, Schubert U, Fischer S, Morgenstern E, Hammes HP, Preissner KT,. The functional role of blood platelet components in angiogenesis. Thromb Haemost 2004; 92: 394-402. (Pubitemid 39177413)
151. Ribatti D,. The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review. Br J Haematol 2005; 128: 303-9. (Pubitemid 40216151)
152. Kut C, Mac Gabhann F, Popel AS,. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer 2007; 97: 978-85. (Pubitemid 47519292)
153. Gunsilius E, Petzer A, Stockhammer G, Nussbaumer W, Schumacher P, Clausen J, Gastl G,. Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 2000; 58: 169-74. (Pubitemid 30113869)
154. Folkman J,. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-86. (Pubitemid 46505878)
155. Dineen SP, Roland CL, Toombs JE, Kelher M, Silliman CC, Brekken RA, Barnett CC, Jr., The acellular fraction of stored platelets promotes tumor cell invasion. J Surg Res 2009; 153: 132-7.
156. Holmes CE, Levis JE, Ornstein DL,. Activated platelets enhance ovarian cancer cell invasion in a cellular model of metastasis. Clin Exp Metastasis 2009; 26: 653-61.
157. Alvarez RH, Kantarjian HM, Cortes JE,. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 2006; 81: 1241-57. (Pubitemid 44316290)
158. Carlson NE, Roach RB, Jr., Platelet-rich plasma: clinical applications in dentistry. J Am Dent Assoc 2002; 133: 1383-6.
159. Ranieri G, Coviello M, Patruno R, Valerio P, Martino D, Milella P, Catalano V, Scotto F, De Ceglie A, Quaranta M, Ribatti D, Pellecchia A,. Vascular endothelial growth factor concentrations in the plasma-activated platelets rich (P-APR) of healthy controls and colorectal cancer patients. Oncol Rep 2004; 12: 817-20.
160. Sledge GW, Jr., Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects. Semin Oncol 2002; 29: 104-10. (Pubitemid 34816072)
161. Yu J, Ustach C, Kim HR,. Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol 2003; 36: 49-59. (Pubitemid 36836256)
162. Wang D, Huang HJ, Kazlauskas A, Cavenee WK,. Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res 1999; 59: 1464-72. (Pubitemid 29160112)
163. Pipili-Synetos E, Papadimitriou E, Maragoudakis ME,. Evidence that platelets promote tube formation by endothelial cells on matrigel. Br J Pharmacol 1998; 125: 1252-7. (Pubitemid 28542534)
164. Arrieta O, Guevara P, Reyes S, Palencia G, Rivera E, Sotelo J,. Paradoxical effect of aspirin on the growth of C6 rat glioma and on time of development of ENU-induced tumors of the nervous system. J Cancer Res Clin Oncol 2001; 127: 681-6. (Pubitemid 32955692)
165. Trikha M, Zhou Z, Timar J, Raso E, Kennel M, Emmell E, Nakada MT,. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res 2002; 62: 2824-33. (Pubitemid 34525767)
166. Ho-Tin-Noe B, Goerge T, Cifuni SM, Duerschmied D, Wagner DD,. Platelet granule secretion continuously prevents intratumor hemorrhage. Cancer Res 2008; 68: 6851-8.
167. Brockmann MA, Bender B, Plaxina E, Nolte I, Erber R, Lamszus K, Groden C, Schilling L,. Differential effects of tumor-platelet interaction in vitro and in vivo in glioblastoma. J Neurooncol 2011; 105: 45-56
168. Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J, Ratajczak MZ,. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 2005; 113: 752-60. (Pubitemid 40101256)
169. Wang Y, Zhang H,. Platelet-induced inhibition of tumor cell growth. Thromb Res 2008; 123: 324-30.
170. Jin DK, Shido K, Kopp HG, Petit I, Shmelkov SV, Young LM, Hooper AT, Amano H, Avecilla ST, Heissig B, Hattori K, Zhang F, et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 2006; 12: 557-67.
171. Italiano JE, Jr., Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, Ryeom S, Folkman J, Klement GL,. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008; 111: 1227-33. (Pubitemid 351213404)